Dear David,
Early development decisions have lasting consequences. Choices made well before Phase 3, around trial design, target product profile, and evidence strategy, can meaningfully shape downstream access, reimbursement, and commercial viability.
In this live webinar, experts from Certara will explore how advanced modeling approaches, including model-based meta-analysis (MBMA) and quantitative systems pharmacology (QSP), can inform high-impact decisions earlier in development—when strategies are still flexible and risk can be actively managed.
Participants will learn how advanced modeling can help HEOR teams:
- Inform Phase 3 go/no-go decisions with greater confidence
- Design Phase 3 studies that better support future reimbursement needs
- Make strategic choices earlier using limited early-phase data
- Strengthen alignment between development strategy and payer expectations
Meet the Speakers
Ananth Kadambi, PhD
VP, Real World Evidence & Modeling Solutions
Certara
Matt Zierhut, PhD MBA
VP, MBMA Capability Lead
Certara
Doug Chung, MS
Sr Director, QSP
Certara
Roman Casciano, MEng
SVP, Evidence & Access
Certara
Register to access expert insights on early-phase decision-making and Phase 3 strategy.
Don’t want to receive these emails? No problem, simply click on the Unsubscribe link below.
By accessing this content, you are permitting Pharma Ignite or a third party to contact you regarding the content (by phone or email).
© 2026 Marketing Masters Hub. All rights reserved.